April 2, 2025 – The 2024 High-Quality Development Leader Enterprise list, jointly released under the guidance of Shenzhen Federation of Industry and Commerce (General Chamber of Commerce) and evaluated by Shenzhen Enterprise High-Quality Development Association in collaboration with Harbin Institute of Technology (Shenzhen) Shenzhen High-Quality Development and New Structure Research Institute, has been announced. Shenzhen Rising Medical Co., Ltd., a park-based enterprise, was proudly recognized as a 2024 High-Quality Development Leader Enterprise.
This authoritative list aims to leverage scientific research, precise analysis, and efficient services to identify emerging technologies, industries, and business models in Shenzhen. It highlights enterprises demonstrating exceptional innovation capabilities, competitiveness, and sustainable development potential, accelerating the formation of new productive forces and reinforcing development momentum for Shenzhen enterprises to achieve steady progress along the high-quality development path.
About Shenzhen Rising Medical Co., Ltd.
As a national high-tech enterprise specializing in R&D, production, and distribution of medical devices, Shenzhen Rising Medical Co., Ltd. focuses on its core product lines:
- Arterial Compression Hemostatic Device Series
- Ultrasound Probe Infection Control Cover Series
These solutions are widely adopted in clinical departments including Cardiac Intervention, Vascular Intervention, Neurointervention, Oncology Intervention, ICU, Ultrasound Department, and Reproductive Centers. Driven by technological innovation, the company delivers self-developed high-quality medical consumables and devices to hospitals, providing efficient and safe clinical solutions that enhance infection control precision and post-operative management.
Our product portfolio closely aligns with multi-departmental needs, balancing professional expertise with versatile applications. Committed to being a trusted partner in interventional medicine and healthcare infection control, we persistently advance the universal accessibility of medical technologies.
